Insilico Medicine has administered the first dose of a generative AI drug to patients in Phase II clinical trial. The compound, INS018_055, has completed Phase 0 and Phase I human safety studies and is now in multi-regional Phase II clinical trials in the US and China.
INS018_055 is a potential anti-fibrosis drug candidate with a novel AI-discovered target and a novel AI-generated molecular structure. The company has already conducted studies on this in mice in 2019.
Insilico Medicine believes that use of the compound could provide an additional treatment option for patients with pulmonary fibrosis worldwide, particularly patients with idiopathic pulmonary fibrosis (IPF), a specific form of pulmonary fibrosis that leads to progressive and irreversible loss of lung function.
“When we started, there were hundreds of companies claiming to use AI for drug discovery. […] We made a bet on generative AI early, tapped Nvidia’s best-in-class technology, worked hard, and now we can tangibly demonstrate substantial R&D performance boosts and real clinical-stage drugs imagined by AI.”
Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Medicine